عربي English Türkçe اردو فارسى
Logo
Latest News
Varieties

WHO Revises COVID-19 Vaccine Recommendations for Omicron-Era

Workers walk on a street in Beijing, China, 27 March, 2023. (EPA)
Workers walk on a street in Beijing, China, 27 March, 2023. (EPA)
TT
TT

WHO Revises COVID-19 Vaccine Recommendations for Omicron-Era

Workers walk on a street in Beijing, China, 27 March, 2023. (EPA)
Workers walk on a street in Beijing, China, 27 March, 2023. (EPA)

The World Health Organization has tailored its COVID-19 vaccination recommendations for a new phase of the pandemic, suggesting that healthy children and adolescents may not necessarily need a shot but older, high-risk groups should get a booster between 6 to 12 months after their last vaccine.

The UN agency said the aim was to focus efforts on vaccinating those facing the greatest threat of severe disease and death from COVID-19, considering the high-level population immunity worldwide due to widespread infection and vaccination.

The health agency defined high-risk populations as older adults, as well as younger people with other significant risk factors. For this group, the agency recommends an additional shot of the vaccine either 6 or 12 months after the latest dose, based on factors such as age and immunocompromising conditions.

Meanwhile, it said healthy children and adolescents were "low priority" for COVID-19 vaccination, and urged countries to consider factors like disease burden before recommending vaccination of this group. It said the COVID-19 vaccines and boosters were safe for all ages, but the recommendations took into account other factors like cost-effectiveness.

The WHO said in September last year that the end of the pandemic was "in sight". In a briefing on Tuesday, the agency said its latest advice reflected the current disease picture and global immunity levels, but should not be seen as long-term guidance over whether annual boosters would be needed.

The recommendations come as countries take differing approaches. Some high-income countries like the United Kingdom and Canada are already offering those at high-risk COVID-19 boosters this spring, six months after their last dose.

"The revised roadmap re-emphasizes the importance of vaccinating those still at-risk of severe disease," said Hanna Nohynek, chair of the WHO's Strategic Group of Experts on immunization, which made the recommendations.

The committee also called for urgent efforts to catch up on routine vaccinations missed during the pandemic and warned of a rise in vaccine-preventable diseases like measles.

For COVID, it said that vaccines beyond the initial two shots and a booster were no longer routinely recommended for those at "medium risk" as benefits were marginal.

Most Viewed

 
 
Varieties

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”